Who Paid My Doc
David Coleman
Optometrist, Vision Therapy Joplin, MO Doctor of Optometry
NPI 1770508889 CMS profile 125817
1030 Se Murphy Blvd, Joplin, MO 64801
General payments
$334
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, David Coleman of Joplin, MO is reported in the CMS Open Payments database as having received $334 across 17 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 43rd percentile of Optometrist, Vision Therapy profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $18 | 1 | |
| 2024 | General | $17 | 1 | |
| 2023 | General | $86 | 4 | |
| 2022 | General | $97 | 3 | |
| 2021 | General | $31 | 2 | |
| 2020 | General | $15 | 1 | |
| 2019 | General | $71 | 5 |
Beside peers
- David Coleman
- Optometrist, Vision Therapy median
- Middle half of Optometrist, Vision Therapy
- National median
In program year 2025, general payments to David Coleman were reported at $18. Among 159 Optometrist, Vision Therapy profiles paid that year, the median was $172 and the middle half received between $65 and $349.
Show as a table
| Year | David Coleman | Optometrist, Vision Therapy median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $71 | $149 | $42–$361 | $163 |
| 2020 | $15 | $59 | $20–$146 | $114 |
| 2021 | $31 | $114 | $43–$217 | $132 |
| 2022 | $97 | $130 | $46–$350 | $149 |
| 2023 | $86 | $153 | $70–$363 | $160 |
| 2024 | $17 | $157 | $71–$362 | $164 |
| 2025 | $18 | $172 | $65–$349 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 2 drugsPart D claims
29
Drug cost
$1,149
Branded share of claims
37.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol | Brand | 11 | $1,048 | |
| Latanoprost | Generic | 18 | $101 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 12 billing codesPaid by Medicare
$4,811
Medicare patients
70
Services billed
121
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 33% | |
| COPD | 27% | |
| Diabetes | 26% | |
| Chronic kidney disease | 26% | |
| Ischemic heart disease | 21% | |
| Depression | 21% | |
| Atrial fibrillation | 17% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
17 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Optometrist, Vision Therapy in Missouri
Related records
Optometrist, Vision Therapy in Missouri
Practitioners in the same specialty and state, ranked by reported value.
All Optometrist, Vision Therapy
Everyone recorded under this specialty, nationwide.
Doctors in Missouri
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.